Organization | Avon Foundation

Avon Foundation Report issue

Foundation Phase 1 Phase 2

Founded: London United Kingdom (1955)

Organization Overview

First Clinical Trial

2005

NCT00232505

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Avon Breast Cancer Foundation

Active Ingredients

Drugs in Phase 2 Trials (9)

allogeneic gm-csf-secreting breast cancer vaccine (1 trial)

amino acids (Freamine) (1 trial)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

durvalumab (imfinzi) (1 trial)

trastuzumab (herceptin) (1 trial)

tremelimumab (Imjudo) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (2)

cyclosporine (sandimmune) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Other Trials (1)

anastrozole (arimidex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial APIs: 12